Thymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platform

Basit Öğe Kaydı
dc.authoridYILDIRIM, Yeliz/0000-0002-3014-4510
dc.authoridKOZGUS GULDU, OZGE/0000-0001-7028-0720
dc.authorwosidYILDIRIM, Yeliz/AAG-5559-2019
dc.authorwosidyildirim, yeliz/AAT-9491-2021
dc.authorwosidMedine, Emin İlker/GLS-0483-2022
dc.authorwosidKOZGUS GULDU, OZGE/GLQ-8246-2022
dc.contributor.authorInce, Iskender
dc.contributor.authorMuftuler, Zumrut Biber
dc.contributor.authorMedine, E. Ilker
dc.contributor.authorGuldu, Ozge Kozgus
dc.contributor.authorTakan, Gokhan
dc.contributor.authorErgonul, Aysegul
dc.contributor.authorParlak, Yasemin
dc.date.accessioned2023-01-12T20:11:45Z
dc.date.available2023-01-12T20:11:45Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancerous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide therapy. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rabbits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6-7-week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers.en_US
dc.description.sponsorshipTurkish Scientific Research Council-Health Sciences Research Support Group (TUBITAK-SBAG), Ankara, Turkey [113S922]; NIH/NCI Cancer Center Support Grant [P30 CA008748]en_US
dc.description.sponsorshipThis project was financially supported by the Turkish Scientific Research Council-Health Sciences Research Support Group (TUBITAK-SBAG; Project No: 113S922), Ankara, Turkey. Omer Aras was supported in part by the NIH/NCI Cancer Center Support Grant P30 CA008748.en_US
dc.identifier.doi10.2174/2211556009666200413085800
dc.identifier.endpage36en_US
dc.identifier.issn1874-4710
dc.identifier.issn1874-4729
dc.identifier.issue1en_US
dc.identifier.pmid32282311en_US
dc.identifier.startpage23en_US
dc.identifier.urihttps://doi.org/10.2174/2211556009666200413085800
dc.identifier.urihttps://hdl.handle.net/11454/78184
dc.identifier.volume14en_US
dc.identifier.wosWOS:000641557600005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherBentham Science Publ Ltden_US
dc.relation.ispartofCurrent Radiopharmaceuticalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectThymoquinoneen_US
dc.subjectthymoquinone glucuronideen_US
dc.subjectmagnetic nanoparticlesen_US
dc.subjectlung canceren_US
dc.subjectiodine-131en_US
dc.subjectSPECTen_US
dc.subjectMRIen_US
dc.subjecttheranosticsen_US
dc.titleThymoquinone Glucuronide Conjugated Magnetic Nanoparticle for Bimodal Imaging and Treatment of Cancer as a Novel Theranostic Platformen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu